BlackRock, Inc. reported beneficial ownership of 2,236,460 shares of BioAge Labs, Inc. common stock, representing 5.03% of the class as of 03/31/2026. The filing shows sole voting power over 2,208,192 shares and sole dispositive power over 2,236,460 shares. The Schedule 13G was signed on 04/27/2026 by Spencer Fleming as Managing Director and states the holdings reflect aggregated Reporting Business Units of BlackRock.
Positive
None.
Negative
None.
Insights
BlackRock holds a >5% passive stake in BioAge, disclosed via Schedule 13G.
BlackRock reports beneficial ownership of 2,236,460 shares or 5.03% as of 03/31/2026. The filing classifies the position under aggregated Reporting Business Units and records sole voting and dispositive powers in the low‑millions of shares.
Passive institutional stakes reported on a 13G typically indicate investment intent without active control; subsequent Form 13D or changes in voting power would signal a shift. Future SEC filings would show any material change in percentage or voting classification.
Filing clarifies voting and disposition powers held by BlackRock entities.
The Schedule 13G lists sole voting power of 2,208,192 shares and sole dispositive power of 2,236,460 shares, indicating centralized voting authority within the Reporting Business Units. The report notes various persons may have economic rights to dividends or proceeds.
Because the statement is a 13G, it frames BlackRock's role as a passive investor under the specified SEC release; any future conversion to an active role would require amended disclosure.
Key Figures
Beneficial ownership:2,236,460 sharesPercent of class:5.03%Sole voting power:2,208,192 shares+3 more
6 metrics
Beneficial ownership2,236,460 sharesBeneficially owned as of 03/31/2026
Percent of class5.03%Percentage of common stock outstanding as reported
Sole voting power2,208,192 sharesShares with sole power to vote
Sole dispositive power2,236,460 sharesShares with sole power to dispose
Report typeSchedule 13GFiling form classification
Signature date04/27/2026Date signed by Managing Director
Key Terms
Schedule 13G, beneficially owned, sole dispositive power, Reporting Business Units
4 terms
Schedule 13Gregulatory
"In accordance with SEC Release No. 34-39538 (January 12, 1998)"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
beneficially ownedfinancial
"Amount beneficially owned: 2236460"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole dispositive powergovernance
"Sole power to dispose or to direct the disposition of: 2236460"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Reporting Business Unitsother
"beneficially owned by certain business units (collectively, the "Reporting Business Units")"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
BioAge Labs, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
09077V100
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
09077V100
1
Names of Reporting Persons
BlackRock, Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
2,208,192.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
2,236,460.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,236,460.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.03 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
BioAge Labs, Inc.
(b)
Address of issuer's principal executive offices:
5885 Hollis Street, Suite 370 Emeryville CA 94608
Item 2.
(a)
Name of person filing:
BlackRock, Inc.
In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)
Address or principal business office or, if none, residence:
BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)
Citizenship:
See Item 4 of Cover Page
(d)
Title of class of securities:
Common Stock
(e)
CUSIP Number(s):
09077V100
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
2236460
(b)
Percent of class:
5.03 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
2208192
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
2236460
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of BioAge Labs, Inc.. No one person's interest in the common stock of BioAge Labs, Inc. is more than five percent of the total outstanding common shares.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See Exhibit 99
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
What stake does BlackRock hold in BioAge Labs (BIOA)?
BlackRock beneficially owns 2,236,460 shares, equal to 5.03% of BioAge Labs common stock as of 03/31/2026. The position is reported on a Schedule 13G aggregated across Reporting Business Units.
Does BlackRock control voting for the BioAge shares it reports?
The filing reports sole voting power over 2,208,192 shares, indicating BlackRock's Reporting Business Units have exclusive voting authority over that portion of the holdings.
Is BlackRock an active manager of BioAge according to this filing?
No. The use of Schedule 13G and the filing language indicate a passive beneficial owner classification under SEC Release No. 34-39538 rather than an active activist or control position.
When were these holdings reported and signed?
The holdings are reported as of 03/31/2026 and the Schedule 13G was signed by Spencer Fleming on 04/27/2026, per the filing cover information.
Who in BlackRock signed the Schedule 13G for BioAge?
The filing is signed by Spencer Fleming, listed as Managing Director, on 04/27/2026, representing the Reporting Business Units that aggregated the holdings.
